Edition:
India

Laboratorios Farmaceuticos ROVI SA (ROVI.MC)

ROVI.MC on Madrid SE C.A.T.S.

24.90EUR
24 Jan 2020
Change (% chg)

€0.60 (+2.47%)
Prev Close
€24.30
Open
€24.20
Day's High
€25.20
Day's Low
€24.20
Volume
11,738
Avg. Vol
15,344
52-wk High
€26.00
52-wk Low
€16.90

Latest Key Developments (Source: Significant Developments)

Rovi Expects 2023 Operating Revenues At About 606 Mln Euros
Monday, 25 Nov 2019 

Nov 25 (Reuters) - Laboratorios Farmaceuticos ROVI SA ::EXPECTS OPERATING REVENUES TO DOUBLE IN 2023 VERSUS OPERATING REVENUES IN 2018 OF 303.2 MILLION EUROS.EXPECTS 2023 EBITDA PRE-RESEARCH AND DEVELOPMENT RECURRENT TO GROW 2.5 TIMES VERSUS EBITDA PRE-RESEARCH AND DEVELOPMENT RECURRENT 2018 OF 63 MILLION EUROS.  Full Article

Rovi 9-Month Net Profit Up At 30.7 Mln Euros YoY
Thursday, 7 Nov 2019 

Nov 7 (Reuters) - Laboratorios Farmaceuticos ROVI SA ::9-MONTH NET PROFIT 30.7 MILLION EUROS VERSUS 15.7 MILLION EUROS YEAR AGO.9-MONTH TOTAL REVENUE 271.6 MILLION EUROS VERSUS 220.0 MILLION EUROS YEAR AGO.9-MONTH EBITDA 47.5 MILLION EUROS VERSUS 25.9 MILLION EUROS YEAR AGO.EXPECTS MID-SINGLE-DIGIT GROWTH RATE FOR OPERATING REVENUE IN 2020.  Full Article

Rovi Q1 Ebitda Up At 11.9 Mln Euros YoY
Wednesday, 8 May 2019 

May 8 (Reuters) - Laboratorios Farmaceuticos ROVI SA ::Q1 TOTAL OPERATING REVENUE 82.2 MILLION EUROS VERSUS 75.8 MILLION EUROS YEAR AGO.Q1 NET PROFIT 6.9 MILLION EUROS VERSUS 6.8 MILLION EUROS YEAR AGO.Q1 EBITDA 11.9 MILLION EUROS VERSUS 10.2 MILLION EUROS YEAR AGO.UPGRADES ITS OPERATING REVENUE GUIDANCE FOR FY 2019, FROM HIGH-SINGLE-DIGIT GROWTH RATE TO LOW-DOUBLE-DIGIT GROWTH RATE.  Full Article

Rovi To Market Teva’s Osteoporosis Treatment For Adults In Spain
Thursday, 11 Apr 2019 

April 11 (Reuters) - Rovi ::ROVI WILL MARKET TEVA’S OSTEOPOROSIS TREATMENT FOR ADULTS TETRIDAR IN SPAIN.IS EXPECTED TO BEGIN MARKETING OF TETRIDAR IN SPAIN IN Q3 2019.  Full Article

Rovi 9-Month Net Profit Down At 15.7 Mln Euros YoY
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Laboratorios Farmaceuticos ROVI SA ::9-MONTH NET PROFIT 15.7 MILLION EUROS VERSUS 17.0 MILLION EUROS YEAR AGO.9-MONTH EBITDA 25.9 MILLION EUROS VERSUS 27.0 MILLION EUROS YEAR AGO.9-MONTH TOTAL REVENUE 220.0 MILLION EUROS VERSUS 204.5 MILLION EUROS YEAR AGO.SEES 2019 GROWTH RATE OF OPERATING REVENUES IN UPPER BAND OF THE 0% - 10% RANGE.INCREASES ITS OPERATING INCOME GUIDANCE FOR 2018 TO HIGH SINGLE DIGIT FROM MID SINGLE DIGIT GROWTH RATE.  Full Article

Rovi Signs Deal For Marketing Of Its Enoxaparin Biosimilar In France
Thursday, 20 Sep 2018 

Sept 20 (Reuters) - Laboratorios Farmaceuticos ROVI SA ::SAYS SIGNS DEAL WITH BIOGARAN FOR MARKETING OF ITS ENOXAPARIN BIOSIMILAR IN FRANCE.SAYS ENOXAPARIN IS USED TO TREAT AND PREVENT DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM.  Full Article

Rovi Signs Distribution Agreement With Sandoz
Tuesday, 12 Jun 2018 

June 12 (Reuters) - Rovi ::REACHES AGREEMENT WITH SANDOZ, A UNIT OF NOVARTIS, FOR DISTRIBUTION AND MARKETING OF ITS ENOXAPARIN BIOSIMILAR.GRANTS SANDOZ AN EXCLUSIVE LICENSE TO MARKET PRODUCT IN HONG KONG, SINGAPORE AND VIETNAM.  Full Article

Rovi Q1 Net Profit Up 7 Pct YoY
Wednesday, 25 Apr 2018 

April 25 (Reuters) - Laboratorios Farmaceuticos ROVI SA ::Q1 REVENUE 76.0 MILLION EUROS VERSUS 67.8 MILLION EUROS YEAR AGO.Q1 NET PROFIT 6.8 MILLION EUROS VERSUS 6.4 MILLION EUROS YEAR AGO.Q1 EBITDA 10.2 MILLION EUROS VERSUS 10.2 MILLION EUROS YEAR AGO.  Full Article

Rovi Sees 2018 Operating Revenue Growth At Mid-Single-Digit Rate
Tuesday, 20 Feb 2018 

Feb 20 (Reuters) - Laboratorios Farmaceuticos ROVI SA (ROVI) ::FOR 2018 SEES A MID-SINGLE-DIGIT GROWTH RATE FOR OPERATING REVENUE WITH A RANGE OF 20 MILLION EURO - 30 MILLION EURO SALES OF ENOXAPARIN BIOSIMILAR‍​.TO PROPOSE A DIVIDEND OF 0.1207 EUROS PER SHARE FOR FY 2017.FY EBITDA DOWN 22 PERCENT AT 30.5 MILLION EUROS VERSUS 39.3 MILLION EUROS YEAR AGO.  Full Article

ROVI FY Net Profit Down At 17.2 Mln Euros
Tuesday, 20 Feb 2018 

Feb 20 (Reuters) - LABORATORIOS FARMACEUTICOS ROVI SA (ROVI) ::FY NET PROFIT 17.2 MILLION EUROS VERSUS 26.1 MILLION EUROS YEAR AGO.FY NET SALES 275.6 MILLION EUROS VERSUS 265.2 MILLION EUROS YEAR AGO.  Full Article